We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current FTXH market cap is 20.39M. The company's latest EPS is USD 2.4547 and P/E is 11.08.
| Quarter End | |||||
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | |||||
| Operating Income | |||||
| Net Income |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 106k | 269k | 301k | 710k | 476k |
| Operating Income | 0 | 0 | 0 | 0 | 0 |
| Net Income | -304k | 3.69M | 1.02M | -156k | 1.84M |
| Quarter End | |||||
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | |||||
| Total Liabilities | |||||
| Total Equity |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 5.81M | 19.14M | 17.32M | 32.66M | 21.01M |
| Total Liabilities | 2k | 9k | 8k | 18k | 10k |
| Total Equity | 5.81M | 19.13M | 17.31M | 32.64M | 21M |
| Market Cap | 20.39M |
| Price to Earnings Ratio | 11.08 |
| Price to Sales Ratio | 42.84 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0.97 |
| Dividend Yield | - |
| Shares Outstanding | 750k |
| Average Volume (1 week) | 1.49k |
| Average Volume (1 Month) | 1.57k |
| 52 Week Change | 0.07% |
| 52 Week High | 29.72 |
| 52 Week Low | 25.73 |
| Spread (Intraday) | 32.3 (74.72%) |
| Company Name | First Trust Nasdaq Pharmaceuticals |
| Address |
155 federal st boston, massachusetts 02110 |
| Website | https:// |
| Industry | mgmt invt offices, open-end (6722) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
